One of the world's largest longitudinal clinical studies investigating the effects of medicinal cannabis on patient quality of life and chronic conditions has delivered positive results across several metrics including fatigue and depression.
Led by the University of Sydney and supported by Health Insurance Fund of Australia (HIF) and Little Green Pharma (ASX: LGP), the Quality of Life Evaluation Study (QUEST Initiative) recently had a 12-month follow-up observation study published in the peer-reviewed journal PLOS One.
Analysis of the 2,353 QUEST Initiative patients showed clinically meaningful improvements across all patients for health-related quality of life (HRQL), fatigue, and sleep, as well as clinically meaningful reductions in anxiety, pain, depression and sleep disorders in patients diagnosed with these conditions.
All participants in the study, which took place between November 2020 and December 2021, used oral medicinal cannabis according to the protocol and had previously experienced unsuccessful results with other standard pharmaceutical treatments.
Perth-based Little Green Pharma exclusively provided Australian-made medicinal cannabis oils to participants at a discounted cost, containing different ratios of active ingredients, with many patients using CBD-only formulations which allowed them to drive during the study.
Participants were recruited across six states by 120 independent doctors, and were aged between 18 and 97 years with an average age of 51, and skewed female at 63 per cent.
"Little Green Pharma is proud to continue leading medicinal cannabis research and supporting this significant study on the effects of medicinal cannabis on patient quality of life," says the company's managing director Paul Long.
"The study's findings are particularly important for Australian doctors, as they demonstrate the effectiveness of Australian-grown medicinal cannabis in treating Australian patients.
TO CONTINUE READING: Business News Australia
Chargement en cours...
